Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) just unveiled an update.
Orexo AB announced its participation in the 2025 EAACI Congress, where it will present clinical data for its nasal rescue medication, OX640. This product, based on the AmorphOX® technology, shows promise for rapid and effective treatment of severe allergic reactions, including anaphylaxis. The clinical study demonstrated that OX640 allows for faster absorption of epinephrine under allergic conditions, suggesting a rapid onset of action. The presentation at EAACI, a leading global association for allergy and immunology diseases, underscores Orexo’s commitment to advancing treatment options in this field.
More about Orexo AB
Orexo is a Swedish pharmaceutical company specializing in developing improved pharmaceuticals using proprietary formulation technologies. The company focuses on addressing large medical needs, particularly in the US market, where it provides treatment solutions for opioid use disorder. Orexo is listed on Nasdaq Stockholm and the OTCQX market in the US.
YTD Price Performance: -17.03%
Average Trading Volume: 13,881
Current Market Cap: SEK498M
See more insights into ORX stock on TipRanks’ Stock Analysis page.